HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced,...
Read More Details
Finally We wish PressBee provided you with enough information of ( Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025 )
Also on site :
- Final Palisades fire evacuation order lifted
- 'Unprecedented' number of US Air Force aerial refueling tankers heading toward Europe
- Chart-Topping 70's Rock Band Honors Fallen Members During Farewell Show